Contributions
Abstract: P850
Type: Poster
Abstract Category: Clinical aspects of MS - Epidemiology
Background: There is compelling evidence that both genetic and environmental factors confer susceptibility to develop multiple sclerosis (MS). Several studies have indicated that the effect of environmental factors may be especially pronounced in adolescence. Few studies have investigated the association between passive smoking and risk of MS. In this study we focused on the association between passive smoking at home and work during the age of 10-19.
Objectives: To investigate the risk of MS in Danish patients and healthy blood donor controls exposed to passive smoking during adolescence.
Methods: All Participants, included from 2009 to 2014, answered a comprehensive lifestyle-environmental factor questionnaire including questions on passive smoking.MS patients were recruited among 2775 individuals from the Danish MS Biobank, 2058 (74%) responded. The control group consisted of blood donors, recruited from five major donor locations. Two places were able to calculate the response rates of 75% and 90%. In total we have questionnaire data from 7289 individuals (2058 cases and 5231 controls). Of these, 529 were excluded due to other ethnicity than Nordic, 248 for age corrections and 35 due to missing data on passive smoking. Finally 1197 cases and 2077 controls were excluded, because of smoking prior to age 20. Thus, we included 3203 individuals (616 patients and 2587 controls). Data on MS diagnosis was retrieved from The Danish Multiple Sclerosis Registry.Logistic regression models were used to investigate the association between passive smoking at age of 10-19 years and the risk of MS between exposed and non-exposed participants. The association was adjusted for sex, year of birth, smoking after 19 years of age and alcohol intake between ages 15-19. The exposure-response relationship was evaluated by including the number of years exposed to passive smoking in the statistical analyses.
Results: Exposure to passive smoking was associated with an overall increased risk of developing MS with an odds ratio (OR) of 1.34, 95 % confidence interval (CI) 1.15-1.57, p < 0.001. Quantifying the passive smoking by measuring in years of exposure, we found an increased risk of MS (OR 1.02, 95% CI 1.007-1.040, p=0.006) for every additional year of being exposed.
Conclusions: In this study we found that exposure to passive smoking during adolescence is associated with an increased risk of developing MS. Further, the risk increases by every additional year of exposure.
Disclosure: Ditte Oturai: nothing to disclose
Helle Bach Søndergaard: has received support for congress participation from TEVA and Genzyme.
Julie Hejgaard Laursen: has received honoraria for lecturing from Merck Serono and has had travel expenses reimbursed by Teva, Almirall and Merck Serono.
Stefan Gustavsen: nothing to disclose
Joachim Thilsted: nothing to disclose
Melinda Magyari: has served on scientific advisory board for Biogen Idec and Novartis, Merck Serono, has received honoraria for lecturing from Biogen Idec, Merck Serono, Novartis, Genzyme, has received support for congress participation from Biogen Idec, Novartis, Genzyme, Teva. Emilie Just-Østergaard: nothing to disclose
Finn Sellebjerg: has served on scientific advisory boards for Biogen Idec, Genzyme, Merck Serono, Novartis, Sanofi-Aventis and Teva, has been on the steering committee of a clinical trial sponsored by Merck Serono, and served as consultant for Biogen Idec and Novo Nordisk; has received support for congress participation from Biogen Idec, Novartis, Genzyme (Sanofi-aventis) and Teva; has received speaker honoraria from Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, Sanofi-Aventis and Schering-Plough. His laboratory has received research support from Biogen Idec, Bayer Schering, Merck Serono, Sanofi-Aventis and Novartis. Lise Wegner Thørner: nothing to disclose.
Henrik Ullum has received honoraria for lecturing from Roche.
Annette Bang Oturai: has served on scientific advisory boards for Biogen Idec; has received research support from Novartis and Biogen Idec; has received speaker honoraria from Biogen Idec, Novartis and TEVA; and has received support for congress participation from, Merck Serono, TEVA, Biogen, Novartis and Genzyme
Abstract: P850
Type: Poster
Abstract Category: Clinical aspects of MS - Epidemiology
Background: There is compelling evidence that both genetic and environmental factors confer susceptibility to develop multiple sclerosis (MS). Several studies have indicated that the effect of environmental factors may be especially pronounced in adolescence. Few studies have investigated the association between passive smoking and risk of MS. In this study we focused on the association between passive smoking at home and work during the age of 10-19.
Objectives: To investigate the risk of MS in Danish patients and healthy blood donor controls exposed to passive smoking during adolescence.
Methods: All Participants, included from 2009 to 2014, answered a comprehensive lifestyle-environmental factor questionnaire including questions on passive smoking.MS patients were recruited among 2775 individuals from the Danish MS Biobank, 2058 (74%) responded. The control group consisted of blood donors, recruited from five major donor locations. Two places were able to calculate the response rates of 75% and 90%. In total we have questionnaire data from 7289 individuals (2058 cases and 5231 controls). Of these, 529 were excluded due to other ethnicity than Nordic, 248 for age corrections and 35 due to missing data on passive smoking. Finally 1197 cases and 2077 controls were excluded, because of smoking prior to age 20. Thus, we included 3203 individuals (616 patients and 2587 controls). Data on MS diagnosis was retrieved from The Danish Multiple Sclerosis Registry.Logistic regression models were used to investigate the association between passive smoking at age of 10-19 years and the risk of MS between exposed and non-exposed participants. The association was adjusted for sex, year of birth, smoking after 19 years of age and alcohol intake between ages 15-19. The exposure-response relationship was evaluated by including the number of years exposed to passive smoking in the statistical analyses.
Results: Exposure to passive smoking was associated with an overall increased risk of developing MS with an odds ratio (OR) of 1.34, 95 % confidence interval (CI) 1.15-1.57, p < 0.001. Quantifying the passive smoking by measuring in years of exposure, we found an increased risk of MS (OR 1.02, 95% CI 1.007-1.040, p=0.006) for every additional year of being exposed.
Conclusions: In this study we found that exposure to passive smoking during adolescence is associated with an increased risk of developing MS. Further, the risk increases by every additional year of exposure.
Disclosure: Ditte Oturai: nothing to disclose
Helle Bach Søndergaard: has received support for congress participation from TEVA and Genzyme.
Julie Hejgaard Laursen: has received honoraria for lecturing from Merck Serono and has had travel expenses reimbursed by Teva, Almirall and Merck Serono.
Stefan Gustavsen: nothing to disclose
Joachim Thilsted: nothing to disclose
Melinda Magyari: has served on scientific advisory board for Biogen Idec and Novartis, Merck Serono, has received honoraria for lecturing from Biogen Idec, Merck Serono, Novartis, Genzyme, has received support for congress participation from Biogen Idec, Novartis, Genzyme, Teva. Emilie Just-Østergaard: nothing to disclose
Finn Sellebjerg: has served on scientific advisory boards for Biogen Idec, Genzyme, Merck Serono, Novartis, Sanofi-Aventis and Teva, has been on the steering committee of a clinical trial sponsored by Merck Serono, and served as consultant for Biogen Idec and Novo Nordisk; has received support for congress participation from Biogen Idec, Novartis, Genzyme (Sanofi-aventis) and Teva; has received speaker honoraria from Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, Sanofi-Aventis and Schering-Plough. His laboratory has received research support from Biogen Idec, Bayer Schering, Merck Serono, Sanofi-Aventis and Novartis. Lise Wegner Thørner: nothing to disclose.
Henrik Ullum has received honoraria for lecturing from Roche.
Annette Bang Oturai: has served on scientific advisory boards for Biogen Idec; has received research support from Novartis and Biogen Idec; has received speaker honoraria from Biogen Idec, Novartis and TEVA; and has received support for congress participation from, Merck Serono, TEVA, Biogen, Novartis and Genzyme